Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,965 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R, Myers J, Chen AI, Schachter L, Yelton R, Ballard HJ, Hodges Dwinal A, Gier S, Victoriano D, Weber E, Napier E, Garfall A, Porter DL, Jäger U, Maziarz RT, Ruella M, Schuster SJ. Ghilardi G, et al. Among authors: weber e. Ann Oncol. 2022 Sep;33(9):916-928. doi: 10.1016/j.annonc.2022.05.521. Epub 2022 Jun 9. Ann Oncol. 2022. PMID: 35690221 Free article.
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Hoda D, Richards R, Faber EA, Deol A, Hunter BD, Weber E, DiFilippo H, Henderson-Clark T, Meaux L, Crivera C, Riccobono C, Garrett A, Jackson CC, Fowler J, Theocharous P, Stewart R, Lorden AL, Porter DL, Berger A. Hoda D, et al. Among authors: weber e. Future Oncol. 2022 Jun;18(19):2415-2431. doi: 10.2217/fon-2022-0162. Epub 2022 May 18. Future Oncol. 2022. PMID: 35583358 Free article.
Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, Barta SK, Chong EA, Frey NV, Gerson JN, Landsburg DJ, Ruella M, Schuster SJ, Svoboda J, Weber E, Porter DL. Nasta SD, et al. Among authors: weber e. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e730-e737. doi: 10.1016/j.clml.2022.04.012. Epub 2022 Apr 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35595619 Free PMC article.
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL. Landsburg DJ, et al. Among authors: weber e. Transplant Cell Ther. 2023 Aug;29(8):495-503. doi: 10.1016/j.jtct.2023.05.011. Epub 2023 May 19. Transplant Cell Ther. 2023. PMID: 37211154
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, Cohen IJ, Gabrielli G, Nasta SD, Porazzi P, Landsburg DJ, Gerson JN, Carter J, Barta SK, Yelton R, Pajarillo R, Patel V, White G, Ballard HJ, Weber E, Napier E, Chong ER, Fraietta JA, Garfall AL, Porter DL, Milone MC, O'Connor R, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: weber e. Blood Adv. 2024 Feb 13;8(3):653-666. doi: 10.1182/bloodadvances.2023011492. Blood Adv. 2024. PMID: 38113468 Free PMC article.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Chong EA, Chong ER, Therwhanger D, Nasta SD, Landsburg DJ, Barta SK, Svoboda J, Gerson JN, Ghilardi G, Paruzzo L, Fraietta JA, Weber E, Stefano N, Porter DL, Frey NV, Garfall AL, Ruella M, Schuster SJ. Chong EA, et al. Among authors: weber e. Transplant Cell Ther. 2024 Mar 16:S2666-6367(24)00288-4. doi: 10.1016/j.jtct.2024.03.015. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38494076
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, Chong EA, Gabrielli G, Nasta SD, Landsburg DJ, Carter J, Pajarillo R, Barta SK, White G, Weber E, Napier E, Porter DL, Garfall AL, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: weber e. J Hematol Oncol. 2024 Apr 22;17(1):19. doi: 10.1186/s13045-024-01542-9. J Hematol Oncol. 2024. PMID: 38644469 Free PMC article.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, Doucette A, Nemecek E, Gabrielli G, Barta SK, Svoboda J, Chong EA, Yelton R, Nasta SD, Landsburg DJ, Ugwuanyi O, Chen AI, Schachter L, White G, Ballard HJ, Weber E, Curley C, Porter DL, Garfall AL, Hwang WT, Guerra CE, Maziarz RT, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: weber e. NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26. NEJM Evid. 2024. PMID: 38776868
1,965 results